The graph presents prostate cancer relative survival rates in the U.S. from 2001 to 2016, showing 1-year, 5-year, and 10-year relative survival percentages based on age groups. The x-axis represents age groups, while the y-axis indicates survival rates at different time intervals. Survival rates remain high across all age groups, with patients aged 65–69 having the highest 10-year survival rate of 99.5%. In contrast, men aged 80 and older have the lowest survival rates, with 92.1% at 1 year and 82.7% at 10 years. The data highlights that younger patients generally experience better long-term survival outcomes.

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

Table Schoenfeld residual test to check the assumption of proportional hazard.

Users can access data about cancer incidence and mortality for all the countries of the world as of 2008. Background GloboCan is a project of the International Agency for Research on Cancer and the World Health Organization (WHO). GloboCan presents estimates of the burden of cancer in 184 countries or territories around the world. User functionality GloboCan provides access to the most recent estimates (from 2008) of the incidence and mortality of 27 major cancers. Users can create fact sheets or do online analysis to create tables, graphs, maps, and predictions. Users c an choose to create tables by population or by cancer type. Covariates for analysis include age group, sex, and continent. Users are able to choose between mortality and incidence statistics. Users can choose to create age specific cancer curves, bar charts, maps, and pie charts. The prediction option allows the user to estimate the future burden of a selected cancer in selected population for a selected year. Data Notes Data sources and methods are clearly outlined on the “Data Sources and Methods” section of the website. Users are able to download their online analysis in PDF or html format. GloboCan uses the definitions outlined in the United Nations, World Population Prospects, 2008 revision (except Cyprus located in Southern Europe and Taiwan is located in Eastern Asia).

Restricted mean survival time, cumulative survival probability, and log rank test of cervical cancer patients at Felege Hiwot Comprehensive Specialized Hospital Oncology Center, Ethiopia (N = 422, March 2021).

The rate of liver cancer diagnoses in the United States increases with age. As of 2021, those aged 75 to 79 years had the highest rates of liver cancer. Risk factors for liver cancer include smoking, drinking alcohol, being overweight or obese, and having diabetes. Who is most likely to get liver cancer? Liver cancer in the United States is much more common among men than women. In 2021, there were 12.3 new liver cancer diagnoses among men per 100,000 population, compared to just five new diagnoses per 100,000 women. Concerning race and ethnicity, non-Hispanic American Indians and Alaska Natives and Hispanic have the highest rates of new liver cancer diagnoses. The five-year survival rate for liver cancer in the United States is around 22 percent, however, this rate is much higher among non-Hispanic Asian and Pacific Islanders than other races and ethnicities. Non-Hispanic Asian and Pacific Islanders have a 33 percent chance of surviving the next five years after a liver cancer diagnosis. Deaths from liver cancer In 2020, there were an estimated 20,262 deaths in the United States due to liver cancer. However, the death rate for liver cancer has decreased over the past few years. In the period 1999 to 2020, the death rate for liver cancer reached a high of five deaths per 100,000 population in 2015 but dropped to 4.6 deaths per 100,000 population by 2020. It is estimated that in 2024, there will be over 19,000 liver and intrahepatic bile duct cancer deaths among men in the United States and 10,700 such deaths among women.

Socio-demographic characteristics of cervical cancer patients in Felege Hiwot Comprehensive Specialized Hospital Oncology Center, Ethiopia (N = 422, March 2021).

Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) in Thailand was reported at 14.5 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Thailand - Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.

Objective: Most sepsis studies have looked at the general population. The aim of this study is to report on the characteristics, treatment and hospital mortality of patients with cancer diagnosed with sepsis or septic shock. Setting: A single-centre retrospective study at a tertiary care centre looking at patients with cancer who presented to our tertiary hospital with sepsis, septic shock or bacteraemia between 2010 and 2015. Participants: 176 patients with cancer were compared with 176 cancer-free controls. Primary and secondary outcomes: The primary outcome of this study was the in hospital mortality in both cohorts. Secondary outcomes included patient demographics, emergency department (ED) vital signs and parameters of resuscitation along with laboratory work. Results: A total of 352 patients were analysed. The mean age at presentation for the cancer group was 65.39±15.04 years, whereas the mean age for the control group was 74.68±14.04 years (p<0.001). In the cancer cohort the respiratory system was the most common site of infection (37.5%) followed by the urinary system (26.7%), while in the cancer-free arm, the urinary system was the most common site of infection (40.9%). intravenous fluid replacement for the first 24 hours was higher in the cancer cohort. ED, intensive care unit and general practice unit length of stay were comparable in both the groups. 95 (54%) patients with cancer died compared with 75 (42.6%) in the cancer-free group. The 28-day hospital mortality in the cancer cohort was 87 (49.4%) vs 46 (26.1%) in the cancer-free cohort (p=0.009). Patients with cancer had a 2.320 (CI 95% 1.225 to 4.395, p=0.010) odds of dying compared with patients without cancer in the setting of sepsis. Conclusions: This is the first study looking at an in-depth analysis of sepsis in the specific oncology population. Despite aggressive care, patients with cancer have higher hospital mortality than their cancer-free counterparts while adjusting for all other variables.

Commentary, charts and tables present information on cancer cases and deaths in the UK. This publication has been discontinued as a result of the ONS Consultation on Statistical Products 2013. The last edition published was in December 2012. Source agency: Office for National Statistics Designation: National Statistics Language: English Alternative title: Cancer incidence and mortality

Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) in Singapore was reported at 10.3 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Singapore - Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.

Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) in Japan was reported at 8 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Japan - Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.

Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) in Egypt was reported at 26 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Egypt - Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.

Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) in Myanmar was reported at 24 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Myanmar - Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.

Results of the bivariable and multivariable Cox regression analysis of cervical cancer patients at Felege Hiwot Comprehensive Specialized Hospital Oncology Center, Ethiopia (N = 422, March 2021).

Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) in Qatar was reported at 12.1 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Qatar - Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.

Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) in Papua New Guinea was reported at 28.5 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Papua New Guinea - Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.

In 2022, there were 18.7 deaths from prostate cancer per 100,000 men in the United States. This statistic shows the prostate cancer death rate in the United States from 1975 to 2022.

Treatment-Related characteristics of cervical cancer patients in Felege Hiwot Comprehensive Specialized Hospital Oncology Center, Ethiopia (n = 422, March 2021).

Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) in South Sudan was reported at 22.4 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. South Sudan - Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 - actual values, historical data, forecasts and projections were sourced from the World Bank on August of 2025.